Now that Resverlogix Corp. has shown positive data in the Phase IIb SUSTAIN trial of RVX-208 to treat atherosclerotic cardiovascular disease, the company is looking to data next half from another Phase IIb trial to show that longer term dosing of RVX-208 actually removes plaque.

RVX-208 met the primary endpoint of increasing HDL-C from baseline to week 24 vs. placebo in SUSTAIN. The study enrolled 176 patients with either stable or acute coronary artery disease (CAD) and low HDL-C who were receiving statins (p=0.001).